Anne-Marie Li-Kwai-Cheung

Ms. Li-Kwai-Cheung joined Wave Life Sciences in 2022 as Senior Vice President, Regulatory Affairs, Compliance and Policy.

Ms. Li-Kwai-Cheung was previously at Roche (Basel, Switzerland), where she started in Global Regulatory Affairs, going on to hold leadership positions of increasing responsibility in global drug development and global program leadership. Within the neurology and rare disease therapeutic areas, Ms. Li-Kwai-Cheung led the global filing and development team through launch of a major therapy for multiple sclerosis, and a global team for a therapy for Huntington’s disease. Her career also reflects her keen interest in personalized medicines, as she led a team focused on the development of novel digital outcome measures for neurological diseases, and software as a medical device (SaMD) to enable physicians and patients to better understand and manage disease progression. Prior to her work at Roche, Ms. Li-Kwai-Cheung worked for Genzyme, leading regulatory teams in regulatory filings and a filing team for an advanced therapy during a period of significant legislative changes. With more than 20 years’ experience of regulatory affairs across major pharmaceutical companies, including GlaxoSmithKline and Wyeth, Ms. Li-Kwai-Cheung has broad experience with the development and execution of strategic regulatory plans that deliver timely and meaningful therapies for patients.